SCOTTSDALE, Ariz., Sept. 29, 2022 /PRNewswire/ — Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting.
Author Archive: AZBio
Anuncia Medical, Inc. Honored with an AZBio Fast Lane Award
Relieving Pressure on the Brain
Cerebrospinal fluid (CSF) normally flows through the cavities (ventricles) of our brains and bathes our brain and spinal column. Hydrocephalus is a condition caused by a buildup of this fluid deep within the brain. The excess fluid puts pressure on the brain. This pressure can damage brain tissues and cause a range of brain function problems. Hydrocephalus can happen at any age, but it occurs more frequently among infants and adults 60 and over.Continue reading
AZBio Kicks of Arizona Bioscience Week on ABC15 (video)
Arizona Bioscience Week has begun. AZBio CEO, Joan Koerber-Walker, kicked things off on ABC15 Arizona and shared highlights of all the exciting things that are happening and how YOU can get connected with Arizona’s Health Innovators.
Check out all of the #AZBW2022 events at https://www.azbio.org/azbw2022 Continue reading
Phoenix Mayor Kate Gallego honored with AZBio Public Service Award
The path for a cure for cancer will run through Phoenix.
Sit down with Phoenix Mayor Kate Gallego and bring up the subject of biosciences, you will experience a burst of energy and insight about the innovation in healthcare taking place across Phoenix, including the growth of businesses creating jobs, and a personal passion that, “the path for a cure for cancer will run through Phoenix.”Continue reading
BMSEED Awarded Grant to develop a physiologically relevant pre-clinical drug screening platform for Alzheimer’s Disease and Traumatic Brain Injury
New Microfluidics Platform with embedded Stretchable Microelectrodes for Research on Alzheimer’s Disease and other Neurological and Neurodegenerative DiseasesContinue reading
Saving money for Medicare by abandoning new drugs for Medicare patients
By Steve Potts, PhD
The new Inflation Reduction Act was written in part to improve access to prescription drugs. But just like many potent drugs, the law too has side effects. As a small biotech drug developer, here’s the most toxic: It’s forcing me to choose to develop a drug for kids instead of a drug for their grandparents, when I could be developing both.Continue reading
Putting Patients First – Biomarker Testing in Arizona
In 2022, ACS CAN led a successful legislative campaign in Arizona to expand access to biomarker testing. Gov. Ducey, Rep. Regina Cobb, Dr. Rachna Shroff and Holly Hill reflect on the impact this law will have on patients across the state.
Dr. Roberta Diaz Brinton is the Arizona Bioscience Researcher of the Year
Roberta Diaz Brinton, PhD is an internationally recognized expert in the cause and treatment of Alzheimer’s disease. Her findings have re-shaped how the field understands the disease and unlocked the potential for new and innovative therapies to prevent and treat Alzheimer’s. Dr. Brinton will be honored by Arizona’s life science and healthcare community at the AZBio Awards on September 28, 2022 at the Phoenix Convention Center. Continue reading
Aqualung Therapeutics Receives the AZBio Fast Lane Award and Achieves Key FDA-Related Milestones
Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the achievement of two key FDA milestones for their therapeutic mAb ALT-100. First is the successful FDA IND submission for the indication of Acute Respiratory Distress Syndrome (ARDS). Second is the scheduling of an FDA Pre-IND type B meeting (September 14th) to discuss the targeted use of ALT-100 mAb in Radiation-induced Lung Injury and Fibrosis.Continue reading